-
Bicycle Therapeutics secures 15-year uranium supply deal for cancer drugs
-
Truist Securities Starts Bicycle Therapeutics (BCYC) at Hold
-
Bicycle Therapeutics (BCYC) PT Raised to $12 at Citizens; Cash Position Strong
-
RBC Capital Downgrades Bicycle Therapeutics (BCYC) to Sector Perform
-
Bicycle Therapeutics plc (BCYC) Tops Q3 EPS by 23c
-
Bicycle Therapeutics Plc (BCYC) 3300 contracts of March 10 calls trade
-
Bicycle Therapeutics adds two directors to board
-
Bicycle Therapeutics (BCYC) PT Lowered to $10 at Citizens JMP
-
Bicycle Therapeutics (BCYC) PT Raised to $27 at RBC Capital
-
Bicycle Therapeutics plc (BCYC) Misses Q2 EPS by 20c
-
Cantor Fitzgerald Reports Key Takeaways from Call With RadioMedia CEO
-
Cantor Fitzgerald reports key Takeaways from call with RadioMedia CEO
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Bicycle Therapeutics (BCYC) PT Raised to $17 at Morgan Stanley
-
Bicycle Therapeutics (BCYC) PT Lowered to $22 at Citizens JMP
-
Bicycle Therapeutics plc (BCYC) Misses Q1 EPS by 3c
-
Bicycle Therapeutics (BCYC) Announces New Board and Key Clinical Leadership Appointments
-
Citizens JMP Reiterates Market Outperform Rating on Bicycle Therapeutics (BCYC)
-
Bicycle Therapeutics plc (BCYC) Tops Q4 EPS by 11c
-
Bicycle Therapeutics (BCYC) PT Lowered to $42 at Jefferies
-
Rodman & Renshaw Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
-
Bicycle Therapeutics Plc (BCYC) Announces Updated Topline Zelenectide Pevedotin Data
-
Bicycle Therapeutics (BCYC) PT Lowered to $17 at B.Riley
-
Bicycle Therapeutics (BCYC) PT Lowered to $33 at H.C. Wainwright
-
Morgan Stanley on Equalweight Rated Bicycle Therapeutics (BCYC): 'We view the ~30%+ down move as overdone'
-
Bicycle Therapeutics (BCYC) PT Lowered to $17 at B.Riley
-
Needham Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
-
Bicycle Therapeutics (BCYC) PT Raised to $32 at Leerink Partners
-
Bicycle Therapeutics plc (BCYC) Tops Q3 EPS by 6c
-
H.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
-
Oppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC)
-
B.Riley Reiterates Neutral Rating on Bicycle Therapeutics (BCYC)
-
Bicycle Therapeutics Plc (BCYC) Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceutic
-
Oppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC)
-
TD Cowen Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
-
H.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
-
B.Riley Downgrades Bicycle Therapeutics (BCYC) to Neutral
-
Bicycle Therapeutics plc (BCYC) Tops Q2 EPS by 36c

